Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Stopped early · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia (CLL)

In brief

This study consists of 2 parts: Phase 1b and Phase 2. Phase 1b will evaluate the safety and tolerability of the combination of idelallisib with the anti-CD37 monoclonal antibody BI 836826 in participants with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and establish the high recommended Phase 2 combination dose (highRP2D) as well as an alternate lower recommended Phase 2 combination dose (lowRP2D). Phase 2 will determine the rates of complete response (CR) and of minimal residual disease (MRD) negativity with the combination at the highRP2D and the lowRP2D in participants with R/R CLL.

Key facts

Study ID
NCT02538614
Run by
Gilead Sciences
People needed
2
Starts
2015-12-29
Expected to finish
2017-07-05
Last updated by the study team
2020-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.